Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition

Margaret Kasner(Thomas Jefferson University), Alexander E. Perl(University of Pennsylvania), James K. Mangan(UC San Diego Health System), John L. Wagner(Leipzig University), Matthew Carabasi(Thomas Jefferson University Hospital), Martin Carroll(University of Pennsylvania), Alison W. Loren(University of Pennsylvania), Rosemarie Mick(University of Pennsylvania), Neal Flomenberg(Memorial Sloan Kettering Cancer Center), Grace R. Jeschke(Georgetown University), Joanne Filicko-O’Hara(Thomas Jefferson University), Noelle V. Frey(Hospital of the University of Pennsylvania), Mark A. Weiss(Thomas Jefferson University), Elizabeth O. Hexner(University of Pennsylvania), Selina M. Luger(University of Pennsylvania)
Investigational New Drugs
April 2, 2018
10.1007/s10637-018-0585-x
Cited by 21

Related Papers

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
|Blood|2001|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Anthracycline Dose Intensification in Acute Myeloid Leukemia
|New England Journal of Medicine|2009|907